The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: fa96daaf0647bced5ad5179e830bd30dae15003c
First added on: Mar 21, 2025